@article{10902/24348,
year = {2021},
url = {http://hdl.handle.net/10902/24348},
abstract = {Background: Vaspin is a novel anti-inflammatory adipokine associated with cardiovascular (CV) disease and inflammation in chronic inflammatory conditions different from axial spondyloarthritis (axSpA). Given the high incidence of CV disease (mainly due to accelerated atherosclerosis) exhibited by axSpA patients, we wondered if vaspin could also be a key molecule in this process. However, data on the role of vaspin regarding atherosclerotic disease in the context of axSpA is scarce. For this reason, we aimed to evaluate the implication of vaspin, at the genetic and serological level, in subclinical atherosclerosis and CV risk in axSpA.
Methods: This study included 510 patients diagnosed with axSpA. Carotid ultrasound (US) was performed to evaluate the presence of subclinical atherosclerosis. Three vaspin gene variants (rs2236242, rs7159023, and rs35262691) were genotyped by TaqMan probes. Serum vaspin levels were assessed by enzyme-linked immunosorbent assay. Statistical analysis was performed using STATA® v.11.1.
Results: Serum vaspin levels were significantly higher in female patients than in males and also in obese patients when compared to those with normal weight (p < 0.05). At the genetic level, we disclosed that the minor allele of rs2236242 (A) was associated with lower serum vaspin levels in axSpA, while the rs7159023 minor allele (A) was linked to higher serum levels (p < 0.05). When the three polymorphisms assessed were combined conforming haplotypes, we disclosed that the TGC haplotype related to high serum levels of vaspin (p = 0.01). However, no statistically significant association was observed between vaspin and markers of subclinical atherosclerosis, both at the genetic and serological level.
Conclusions: Our results revealed that vaspin is linked to CV risk factors that may influence on the atherosclerotic process in axSpA. Additionally, we disclosed that serum vaspin concentration is genetically modulated in a large cohort of patients with axSpA.},
organization = {This work was partially supported by funds of a NEXT-VAL grant (NVAL17/10) (Instituto de Investigación Sanitaria IDIVAL) awarded to FG. RL-M is a recipient of a Miguel Servet type I programme fellowship (grant CP16/00033) from
the “Instituto de Salud Carlos III” (ISCIII) and co-funded by the European Social Fund, ESF). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) from ISCIII and co-funded by the European Regional Development Fund. VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL18/01). LL-G is supported by funds of a Miguel Servet type I programme fellowship from ISCIII (grant CP16/00033, co-funded by the ESF). OG is beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10.},
publisher = {BioMed Central},
publisher = {Arthritis Res Ther
. 2021 Apr 13;23(1):111.},
title = {Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study},
author = {Rueda Gotor, Javier and López Mejías, Raquel and Remuzgo Pérez, Lorena and Pulito Cueto, Verónica and Corrales Martínez, Alfonso and Lera Gómez, Leticia and Portilla González, Virginia and González Mazón, Íñigo and Blanco Alonso, Ricardo and Expósito, Rosa and Mata, Cristina and Llorca Díaz, Francisco Javier and Hernández Hernández, Vanesa and Rodríguez Lozano, Carlos and Barbarroja, Nuria and Ortega Castro, Rafaela and Vicente, Esther and Fernández Carballido, Cristina and Martínez Vidal, María Paz and Castro Corredor, David and Anino Fernández, Joaquín and Peiteado, Diana and Plasencia Rodríguez, Chamaida and Galíndez-Agirregoikoa, Eva and García-Vivar, María Luz and Gualillo, Oreste and Quevedo-Abeledo, Juan Carlos and Castañeda, Santos and Ferraz-Amaro, Iván and González-Gay Mantecón, Miguel Ángel and Genre, Fernanda},
}